Welcome to HTA Audit
Financing and organisation of the health care system are areas of social life which are subject to constant change both in Poland as well as worldwide. Therefore, it is of key importance that decisions in these areas always be taken in an objective way and basing on the most current knowledge.
Such an approach may in consequence lead to improvement of the health care system with regard to:
We are looking forward to cooperating with you!
HTA Audit has operated on the market since 2008. By way of the Associates’ decision, in November 2010 it took the form of a general partnership.
We deal with quality assessment (audit) of clinical and economic studies in the field of health care, health technology assessment reports. We meet our clients’ expectations in the area of strategic decision making with regard to pricing of drugs and medical technologies, negotiations and risk-sharing.
We employ qualified analysts who meet the criteria of proficient command of English, thoroughness and perceptiveness, ability of fast learning, teamwork and self-reliance, an innovative approach to solving problems, and above all a thorough knowledge in the areas of:
In times of limited resources available in health care, it is important that valuable therapeutic or diagnostic technologies can be within reach of patients who need them. It is also essential that ineffective, non-cost effective, and above all harmful technologies are eliminated from daily clinical practice. We believe that by controlling the quality of reimbursement documentation in the broad sense, our activities contribute to taking equitable reimbursement decisions in the health care system.
Therefore HTA Audit is not engaged in business, marketing or public relations activities.
We provide a reliable, objective and professional approach to every project.
An audit serves as a quality benchmark for analyses included in the health technology assessment report. The assessment of the study pertains to its usefulness in the decision-making process regarding reimbursement, i.e. the possibility of it being used in examining applications for financing of health technologies from public funds regarding the criteria for taking reimbursement decisions (in the broad sense of that term).
To accommodate the Commissioning Party’s needs, HTA Audit provides two types of audit:
The Commissioning Party is allowed to use parts of the Opinion or other reviews without indicating the authors’ names, the Contractor’s logo nor name, always presenting the position as its own.
HTA Audit carries out comprehensive horizon scanning of the medical area of choice along with a critical appraisal of available sources of medical information. CETR includes both an analysis of the competition (justification for the selection of comparators for the health technology in question) as well as the possible market access strategies related to introducing the said health technology into the Polish market. For the purpose of determining the technology’s market potential we perform an assessment of the said health technology’s therapeutic and pharmacological innovativeness and determine the added value in comparison to possible treatment options. Assessment of the said technology’s strength of intervention takes into account the level of uncertainty of estimates. With the above-mentioned data in mind we determine the most likely future effective price of the health technology in question or those from beyond the horizon adjusted by price erosion and possible types of RSS.
Main areas of the system analyses are:
HTA Audit prepares and coordinates drafting of the HTA report on behalf of the Commissioning Party. HTA Audit commissions preparation of the HTA report to a company which provides such services. HTA Audit supervises the works at each stage of drafting of the report. After the report has been drafted, HTA Audit performs an audit of the report, both in terms of content and of meeting the formal requirements included in the guidelines of the Agency for Health Technology Assessment and Tariff System in Poland and the regulation of the Minister of Health of 2 April 2012 on minimum requirements to be met by analyses and provisions of the Act of 12 May 2011 on reimbursement.
In result the Commissioning Party receives high-quality reimbursement applications, verified and ready for submission.
Our clients are the biggest pharmaceutical companies and manufacturers of medical devices.
We performed HTA audits and other studies audits for the majority of Polish companies which prepare HTA analyses.
Our clients include foreign partners.
“HTA” Kordecka Spółka Jawna
30-201 Kraków, ul. Emaus 7/9
NIP: 675 144 04 12, REGON: 12 13 75 829,
National Court Registry No. 0000369216
phone +48 12 42 22 381
We employ graduates of Public Health, economist